DescriptionSources: http://news.cancerconnect.com/wp-content/uploads/2010/06/bleomycin.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdfhttp://www.drugbank.ca/drugs/DB00290#targetsCurator's Comment:: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf
Sources: http://news.cancerconnect.com/wp-content/uploads/2010/06/bleomycin.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdfhttp://www.drugbank.ca/drugs/DB00290#targets
Curator's Comment:: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf
Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Bleomycin has antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5953301 | https://www.ncbi.nlm.nih.gov/pubmed/23060708http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(1967)20:5%3C891::AID-CNCR2820200550%3E3.0.CO;2-V/pdf
Curator's Comment:: Umezawa et al (Institute of Microbial Chemistry, Tokyo National Institute of Health, Tokyo, Japan)
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 |
20.0 µM [Kd] | ||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | BLEOMYCIN SULFATE Approved UseBleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents:
Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer.
Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma.
Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma.
Bleomycin for Injection, USP has also been shown to be useful in the management of:
Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. Launch Date1.12924803E11 |
|||
| Primary | BLEOMYCIN SULFATE Approved UseBleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents:
Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer.
Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma.
Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma.
Bleomycin for Injection, USP has also been shown to be useful in the management of:
Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. Launch Date1.12924803E11 |
|||
| Primary | BLEOMYCIN SULFATE Approved UseBleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents:
Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer.
Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma.
Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma.
Bleomycin for Injection, USP has also been shown to be useful in the management of:
Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. Launch Date1.12924803E11 |
|||
| Primary | BLEOMYCIN SULFATE Approved UseBleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents:
Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer.
Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma.
Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma.
Bleomycin for Injection, USP has also been shown to be useful in the management of:
Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. Launch Date1.12924803E11 |
|||
| Primary | BLEOMYCIN SULFATE Approved UseBleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents:
Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer.
Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma.
Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma.
Bleomycin for Injection, USP has also been shown to be useful in the management of:
Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. Launch Date1.12924803E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
|||
| Primary | BLENOXANE Approved UseBLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. Launch Date1.74355202E11 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Biochemical effects of bleomycin A2 on Novikoff hepatoma ascites cells. | 1975 |
|
| Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. | 1988 Sep |
|
| Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. | 1989 Oct |
|
| Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and nongenotoxic carcinogens. | 1999 Aug |
|
| Nucleic Acid recognition by metal complexes of bleomycin. | 1999 Sep 8 |
|
| Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. | 2000 May |
|
| Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. | 2001 Aug 7 |
|
| Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. | 2001 Jun |
|
| An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. | 2002 Oct 15 |
|
| Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice. | 2003 |
|
| CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. | 2003 Dec 21 |
|
| Dual roles of IL-4 in lung injury and fibrosis. | 2003 Feb 15 |
|
| The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. | 2004 Dec |
|
| Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. | 2004 Dec |
|
| ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. | 2004 Jun |
|
| ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha IN THE DEVELOPMENT OF BLEOMYCIN-INDUCED LUNG INJURY. | 2005 Dec |
|
| Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. | 2005 Dec |
|
| [Effects of valsartan on bleomycin-induced pulmonary fibrosis in rats and the expression of hepatocyte growth factor in lung tissue]. | 2005 Jul |
|
| Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. | 2007 Aug 10 |
|
| Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease? | 2007 Jun |
|
| Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. | 2007 Jun 1 |
|
| Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone. | 2007 Jun 13 |
|
| DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. | 2008 Jan |
|
| Cerebellar dysfunction caused by procarbazine and consumption of excessive amount of bananas. | 2008 Jun |
|
| Agents associated with lung inflammation induce similar responses in NCI-H292 lung epithelial cells. | 2008 Oct |
|
| Radiation-induced cathepsin S is involved in radioresistance. | 2009 Apr 15 |
|
| Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. | 2010 Aug |
|
| C/EBPβ-Thr217 phosphorylation signaling contributes to the development of lung injury and fibrosis in mice. | 2011 |
|
| Anti-inflammatory and antifibrotic effects of methyl palmitate. | 2011 Aug 1 |
|
| Links between DNA polymerase beta expression and sensitivity to bleomycin. | 2011 Mar 15 |
|
| Removal of reactive oxygen species-induced 3'-blocked ends by XPF-ERCC1. | 2011 Nov 21 |
|
| The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. | 2012 Jan |
|
| Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. | 2013 Aug |
|
| Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study. | 2013 May 23 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: Bleomycin can be given intramuscularly, or subcutaneously in Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease and as a single dose bolus intrapleural injection (60 units) in Malignant Pleural Effusion.
The main components of Bleomycin for Injection are bleomycins A2 and B2.
Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma - 0.25 to 0.50 units/kg
(10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Route of Administration:
Other
Purified nucleolar DNA was markedly degraded at a concentration of 13 ug/ml by bleomycin A2; bleomycin concentrations 20-30 times greater were required to degrade nucleoplasmic DNA. Whole nuclear DNA was degraded to only a small extent at 13 ug/ml but was markedly degraded at higher bleomycin concentrations.
| Substance Class |
Mixture
Created
by
admin
on
Edited
Sat Jun 26 18:20:17 UTC 2021
by
admin
on
Sat Jun 26 18:20:17 UTC 2021
|
| Record UNII |
40S1VHN69B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
116
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
WHO-VATC |
QL01DC01
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
NCI_THESAURUS |
C2311
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
NDF-RT |
N0000180854
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
FDA ORPHAN DRUG |
118498
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
FDA ORPHAN DRUG |
326510
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
||
|
WHO-ATC |
L01DC01
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4742
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
Bleomycin
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
1622
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | RxNorm | ||
|
SUB00842MIG
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
3208
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
CHEMBL3039590
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
D001761
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
11056-06-7
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
11056-06-7
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
C313
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
40S1VHN69B
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
M2589
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | Merck Index | ||
|
DB00290
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
BLEOMYCIN
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY | |||
|
2721
Created by
admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||